Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Male or female adult ≥ 18 years of age;
• Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
‣ EASI score of 16 or greater,
⁃ IGA score of 3 or greater
⁃ BSA of 10% or greater,
Locations
United States
New Jersey
Eczema Treatment Center of New Jersey
RECRUITING
East Windsor
Contact Information
Primary
Elise Nelson
enelson@windsordermatology.com
6094434500
Time Frame
Start Date: 2022-04-19
Estimated Completion Date: 2024-12-15
Participants
Target number of participants: 40
Treatments
Experimental: Dupixent and Narrowband UVB
Dupixent and Narrowband UVB
Related Therapeutic Areas
Sponsors
Collaborators: Regeneron Pharmaceuticals
Leads: Psoriasis Treatment Center of Central New Jersey